Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial
ConclusionBK-SE36/CpG was well-tolerated and immunogenic. These results pave the way for further proof-of-concept studies to demonstrate vaccine efficacy.Clinical trial registrationhttps://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=1921, PACTR201701001921166.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: African Health | Allergy & Immunology | Burkina Faso Health | Children | Clinical Trials | Headache | Japan Health | Malaria | Malaria Vaccine | Migraine | Pain | Rabies | Study | Vaccines